Enhertu for HER2-Low Breast Cancer: Patient-Reported Outcomes

episode

Breastcancer.org Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded14 Sep 2022

Publisherfeeds.megaphone.fm ↗

Handlerec:11088160

Show notes

At the European Society for Medical Oncology Congress 2022, Dr. Naoto Ueno presented patient-reported quality-of-life outcomes from the DESTINY-Breast04 study, which found that compared to doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer. Listen to the episode to her Dr. Ueno explain: how the researchers assessed quality of life the results showing that Enhertu offered better quality of life than the doctors’ choice of chemotherapy differences in side effects between Enhertu and chemotherapy

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in